Dexcom Inc DXCM
We take great care to ensure that the data presented and summarized in this overview for DEXCOM INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DXCM
View all-
Vanguard Group Inc Valley Forge, PA44.6MShares$5.86 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY33.9MShares$4.46 Billion0.11% of portfolio
-
State Street Corp Boston, MA16.2MShares$2.13 Billion0.1% of portfolio
-
Baillie Gifford & CO15.7MShares$2.06 Billion1.72% of portfolio
-
Capital Research Global Investors Los Angeles, CA13.4MShares$1.76 Billion0.43% of portfolio
-
Sands Capital Management, LLC Arlington, VA10.9MShares$1.43 Billion4.43% of portfolio
-
Geode Capital Management, LLC Boston, MA9.18MShares$1.21 Billion0.12% of portfolio
-
Capital World Investors Los Angeles, CA8.07MShares$1.06 Billion0.19% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL7.26MShares$953 Million0.31% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.77MShares$758 Million1.23% of portfolio
Latest Institutional Activity in DXCM
Top Purchases
Top Sells
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Transactions at DXCM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
2,423
-5.7%
|
$305,298
$126.58 P/Share
|
|
Apr 30
2024
|
Michael Jon Brown EVP Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
629
-0.91%
|
$79,254
$126.25 P/Share
|
|
Apr 15
2024
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
1,990
-4.49%
|
$272,630
$137.81 P/Share
|
|
Apr 08
2024
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
49,633
-7.74%
|
$6,849,354
$138.34 P/Share
|
|
Mar 28
2024
|
Michael Jon Brown EVP Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,624
-1.84%
|
$367,360
$140.38 P/Share
|
|
Mar 25
2024
|
Sadie Stern EVP Chief Human Resources |
SELL
Open market or private sale
|
Direct |
4,137
-5.14%
|
$579,180
$140.0 P/Share
|
|
Mar 15
2024
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
4,203
-2.97%
|
$546,390
$130.45 P/Share
|
|
Mar 12
2024
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
SELL
Open market or private sale
|
Direct |
6,710
-12.14%
|
$899,140
$134.41 P/Share
|
|
Mar 12
2024
|
Teri L Lawver EVP Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,764
-6.67%
|
$638,376
$134.41 P/Share
|
|
Mar 12
2024
|
Jacob Steven Leach EVP Chief Operating Officer |
SELL
Bona fide gift
|
Direct |
7,736
-2.82%
|
-
|
|
Mar 12
2024
|
Jacob Steven Leach EVP Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
14,639
-5.07%
|
$1,961,626
$134.41 P/Share
|
|
Mar 12
2024
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
81,007
-4.23%
|
$10,773,931
$133.19 P/Share
|
|
Mar 12
2024
|
Sadie Stern EVP Chief Human Resources |
SELL
Open market or private sale
|
Direct |
20,321
-3.61%
|
$2,682,372
$132.67 P/Share
|
|
Mar 12
2024
|
Jereme M Sylvain EVP Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,661
-12.0%
|
$1,562,574
$134.41 P/Share
|
|
Mar 12
2024
|
Michael Jon Brown EVP Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,799
-10.98%
|
$1,179,066
$134.41 P/Share
|
|
Mar 08
2024
|
Michael Jon Brown EVP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,711
+21.32%
|
-
|
|
Mar 08
2024
|
Matthew Vincent Dolan EVP Strategy and Corporate Dev |
BUY
Grant, award, or other acquisition
|
Direct |
21,711
+28.2%
|
-
|
|
Mar 08
2024
|
Teri L Lawver EVP Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,053
+26.73%
|
-
|
|
Mar 08
2024
|
Jacob Steven Leach EVP Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,053
+8.28%
|
-
|
|
Mar 08
2024
|
Kevin R Sayer President CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
51,692
+11.09%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 323K shares |
|---|---|
| Bona fide gift | 33.6K shares |
| Open market or private sale | 305K shares |
|---|---|
| Sale (or disposition) back to the issuer | 22.6K shares |
| Bona fide gift | 41.4K shares |